An Hepatitis C Virus (HCV)/HIV Co-Infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin

Noboru Hirashima; Hiroaki Iwase; Masaaki Shimada; Junji Imamura; Wataru Sugiura; Yoshiyuki Yokomaku; Tsunamasa Watanabe

doi:10.2169/internalmedicine.54.4344

CASE REPORTS

An Hepatitis C Virus (HCV)/HIV Co-Infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin

Noboru Hirashima, Hiroaki Iwase, Masaaki Shimada, Junji Imamura, Wataru Sugiura, Yoshiyuki Yokomaku, Tsunamasa Watanabe

Author information

Noboru Hirashima
Department of Gastroenterology, National Hospital Organization Nagoya Medical Center, Japan
Hiroaki Iwase
Department of Gastroenterology, National Hospital Organization Nagoya Medical Center, Japan
Masaaki Shimada
Department of Gastroenterology, National Hospital Organization Nagoya Medical Center, Japan
Junji Imamura
Department of Infectious Diseases and Immunology Clinical Research Center, National Hospital Organization Nagoya Medical Center, Japan
Wataru Sugiura
Department of Infectious Diseases and Immunology Clinical Research Center, National Hospital Organization Nagoya Medical Center, Japan
Yoshiyuki Yokomaku
Department of Infectious Diseases and Immunology Clinical Research Center, National Hospital Organization Nagoya Medical Center, Japan
Tsunamasa Watanabe
Department of Infectious Diseases and Immunology Clinical Research Center, National Hospital Organization Nagoya Medical Center, Japan
Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Japan

Keywords: hepatitis C virus, human immunodeficiency virus, co-infection, simeprevir, peginterferon-alpha, severe hepatitis

JOURNAL OPEN ACCESS

2015 Volume 54 Issue 17 Pages 2173-2177

DOI https://doi.org/10.2169/internalmedicine.54.4344

Details

Abstract

We herein describe the case of a 42-year-old man who developed severe hepatitis caused by hepatitis C virus (HCV) infection at 14 years after the start of human immunodeficiency virus (HIV) treatment. Surprisingly, the levels of alanine aminotransferase (ALT) fluctuated, reaching a peak higher than 1,000 IU/L during chronic HCV infection, and the hepatic histology showed advanced liver fibrosis at 3 years after the primary HCV infection. He was treated with simeprevir, peginterferon-alpha, and ribavirin with a sustained viral response. We conclude that HCV/HIV co-infected patients need to commence anti-HCV therapy when the levels of ALT fluctuate severely under successful HIV control.

Corresponding author

Register with J-STAGE for free!